With over 130 products on the market worth $50bn, biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical compounds today, . Mirroring this trend, the market for lyophilising these entities, currently approaching 200 million units, is set to continue its year-on-year double digit growth.Without lyophilisation, 60% of biotherapeutics including recombinant proteins, plasma, vaccines and antibodies could not be commercially available. Freeze-drying has become increasingly efficient in recent years, easier to use, more cost-effective and extremely accurate. It imparts higher stability, broader temperature tolerance, and longer shelf life to pharmaceutical formulations unstable in aqueous solution.Although the commonest way to ensure longevity and stability for complex molecules, lyophilization however remains costly, complex and facility-intensive. Fine-tuning cycle parameters and trial-and-error experimentation also means the procedure remains as much of an art as a science. As reducing development time becomes increasingly important in today